Soleno Therapeutics Inc


Prices are adjusted according to historical splits.

Soleno Therapeutics Inc Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$41.07 million
Book Value:
Revenue TTM:
Operating Margin TTM:
Gross Profit TTM:
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

Soleno Therapeutics Inc had its IPO on 2014-11-13 under the ticker symbol SLNO.

The company operates in the Healthcare sector and Biotechnology industry. Soleno Therapeutics Inc has a staff strength of 25 employees.

Stock update

Shares of Soleno Therapeutics Inc opened at $4.11 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $3.82 - $4.21, and closed at $4.

This is a -2.68% slip from the previous day's closing price.

A total volume of 62,210 shares were traded at the close of the day’s session.

In the last one week, shares of Soleno Therapeutics Inc have slipped by -19.68%.

Soleno Therapeutics Inc's Key Ratios

Soleno Therapeutics Inc has a market cap of $41.07 million, indicating a price to book ratio of 0.4939 and a price to sales ratio of 0.

In the last 12-months Soleno Therapeutics Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-26836000. The EBITDA ratio measures Soleno Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Soleno Therapeutics Inc’s operating margin was 0% while its return on assets stood at -53.08% with a return of equity of -173.82%.

In Q2, Soleno Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Soleno Therapeutics Inc’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $-2.89 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Soleno Therapeutics Inc’s profitability.

Soleno Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0.5162. Its price to sales ratio in the trailing 12-months stood at 0.

Soleno Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$30.94 million
Total Liabilities
$8.80 million
Operating Cash Flow
Capital Expenditure
Dividend Payout Ratio

Soleno Therapeutics Inc ended 2023 with $30.94 million in total assets and $0 in total liabilities. Its intangible assets were valued at $30.94 million while shareholder equity stood at $12.43 million.

Soleno Therapeutics Inc ended 2023 with $0 in deferred long-term liabilities, $8.80 million in other current liabilities, 10000.00 in common stock, $-254253000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $19.37 million and cash and short-term investments were $19.37 million. The company’s total short-term debt was $212,000 while long-term debt stood at $0.

Soleno Therapeutics Inc’s total current assets stands at $20.50 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $3.44 million and inventory worth $0.

In 2023, Soleno Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Soleno Therapeutics Inc paid $0 in dividends in 2023.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

Soleno Therapeutics Inc stock is currently trading at $4 per share. It touched a 52-week high of $6.2 and a 52-week low of $6.2. Analysts tracking the stock have a 12-month average target price of $12.33.

Its 50-day moving average was $4.75 and 200-day moving average was $3.38 The short ratio stood at 2.86 indicating a short percent outstanding of 0%.

Around 1099.2% of the company’s stock are held by insiders while 6635.8% are held by institutions.

Frequently Asked Questions About Soleno Therapeutics Inc

The stock symbol (also called stock or share ticker) of Soleno Therapeutics Inc is SLNO

The IPO of Soleno Therapeutics Inc took place on 2014-11-13

Similar Industry Stocks (Biotechnology)

Last Price

Most Active

Last Price
Amyris Inc (AMRS)
Humbl Inc (HMBL)

Top Gainers

Last Price
Latch Inc (LTCHW)

Top Losers

Last Price


Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.


203 Redwood Shores Parkway, Redwood City, CA, United States, 94065